Pharming Group N.V. (NASDAQ:PHAR) Q3 2024 Earnings Conference Call October 24, 2024 7:30 AM ET
Company Participants
Sijmen de Vries - Chief Executive Officer & Executive Director
Stephen Toor - Chief Commercial Officer
Anurag Relan - Chief Medical Officer
Jeroen Wakkerman - Chief Financial Officer
Conference Call Participants
Sushila Hernandez - Kempen
Joe Pantginis - H.C. Wainwright
Simon Scholes - First Berlin
Operator
Good day, and thank you for standing by. Welcome to the Pharming Group NV 3Q 2024 Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be question-and-answer session. [Operator Instructions] Please be advised today's conference is being recorded.
I'd now like to hand the conference over to your first speaker today, Sijmen de Vries. Please go ahead.
Sijmen de Vries
Thank you very much, and good morning, good afternoon, ladies and gentlemen. Welcome to our results call. I'm happy, I'm here with the -- to introduce my colleagues here, Stephen Toor, Chief Commercial Officer; Anurag Relan, our Chief Medical Officer; and Jeroen Wakkerman, our Chief Financial Officer, and we will take you through the results and obviously answer all your questions.
So before I do that, I'd like to have the next slide and point you to the forward-looking statements because during this presentation, we will be making the usual forward-looking statements, which, of course, are expressions of our expectations, which can differ significantly, of course, from future results.
So having said that, I would like to start with the next slide. You see a slide of my face there. And you're seeing no doubt the announcement that after 16 years here at the helm, which is actually precisely next week, I have informed the Board of Directors that I will not be available for reelection. The company is in great shape today. So we have -- and I'm reaching a beautiful age of 65 next week. So it would be a good moment to basically hand over the helm to a successor who can continue to build the company as we have been over the last few years into this rare disease company that we are building as we speak with a great pipeline and with a global geographical presence.
And having said that, I would like them to go to the next slide because they see how we are going to build that. RUCONEST, obviously, on the slide number 5, please. On the next -- RUCONEST is, of course, the pillar of the company has been the pillar for a long time. And you see the results of RUCONEST continues to grow more prescribers, more patients using RUCONEST in this increasingly competitive hereditary angioedema market, resulting in a plus in the three quarter results of more than almost $64 million and almost $173 million for nine months in 2023.